That’s where Tempus AI (TEM) enters the picture. Going public just last year, Tempus is already experiencing sharp revenue ...

Tempus AI, Inc. (NASDAQ:TEM) is one of the 11 Best Performing IPOs in the Last 2 Years. The stock’s price target is raised ...

With the AI healthcare market forecast to top $800 billion, can Tempus claim just 2.5% of that? It’s possible, especially if it captures more R&D spending from big pharma. For context, just five ...

Ace hedge fund manager Cathie Wood’s ARK Invest ETFs (exchange-traded funds) have been offloading shares of Roku ($ROKU) and ...

Tempus AI's strategic deals and the Paige acquisition create a deep, defensible data moat. Read why I recommend building ...

Tempus (TEM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

On Tuesday, Cathie Wood-led Ark Invest sold shares of Tempus AI Inc (NASDAQ: TEM) through ARK Genomic Revolution ETF (ARKG) ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

Tempus AI's data and services segment is seeing robust revenue growth, fueled by data licensing. Read why I reiterate my ...

The market environment has been heavily influenced by the changes in monetary policies and global economic uncertainties.

Investing.com -- Tempus AI, Inc. (NASDAQ:TEM) stock surged 16% Thursday morning following the company’s announcement that it received 510 (k) clearance from the U.S. Food and Drug Administration for ...

The ARKG ETF has been particularly active in accumulating biotech stocks, including Atai Life Sciences NV (NASDAQ:ATAI) and Intellia Therapeutics Inc (NASDAQ:NTLA), pointing to a potential long-term ...